CLOSED STUDIES / Ovarian Cancer


GEICO 0701/ICON-7


Title

Randomized “Gynaecologic Cancer InterGroup”, two-group, multi-center study to add bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients suffering from epithelial ovarian cancer.


EudraCT

2005 – 003929 – 22


GEICO Coordinator

Dr. Andres Cervantes


Patients Recruited

41 patients


Inclusion Closing Date

February of 2009


Publication

ESMO 2010. LBA4. ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC) T. Perren, A.M. Swart, J. Pfisterer, J. Ledermann, A. Lortholary, G. Kristensen, M. Carey, P. Beale, A. Cervantes, A. Oza on behalf of GCIG ICON7 collaborators.